Laboratory of Computational and Systems Biology, School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
Chem Biol Drug Des. 2011 Oct;78(4):679-88. doi: 10.1111/j.1747-0285.2011.01202.x. Epub 2011 Sep 6.
Microsomal prostaglandin E synthase-1 (mPGES-1) is the key enzyme for prostaglandin E2 (PGE2) generation during inflammation and is a potential target for designing anti-inflammatory drugs. Potential inhibitors of m-PGES-1 were selected from traditional Chinese medicine (TCM Database@Taiwan) based on the pharmacophore map generated by the top HypoGen hypothesis and validated using structure- and ligand-based analysis. Key features for potential m-PGES-1 inhibitors include pi-interactions and H-bond donors. TCM compounds, shanciol B, shanciol A, castilliferol, and aurantiamide acetate, contoured to the quantitative structure-activity relationship pharmacophore and exhibited high docking scores and binding stability with m-PGES-1. Bioactivity models multiple linear regression (MLR) and support vector machine also supported activity predictions for the candidate compounds. Our results indicate that the investigated TCM compounds could be of use for development into mPGES-1 inhibitors.
微粒体前列腺素 E 合酶-1(mPGES-1)是炎症过程中前列腺素 E2(PGE2)生成的关键酶,也是设计抗炎药物的潜在靶点。基于 HypoGen 假说生成的药效团图,从中药数据库(TCM Database@Taiwan)中筛选出 m-PGES-1 的潜在抑制剂,并通过基于结构和配体的分析进行验证。潜在 m-PGES-1 抑制剂的关键特征包括π相互作用和氢键供体。与定量构效关系药效团吻合的中药化合物山慈菇 B、山慈菇 A、castilliferol 和aurantiamide 醋酸盐,表现出与 m-PGES-1 较高的对接分数和结合稳定性。生物活性模型多元线性回归(MLR)和支持向量机也支持候选化合物的活性预测。我们的结果表明,所研究的中药化合物可能可用于开发 mPGES-1 抑制剂。